Epidemics
Intro -- Contents -- Preface -- Chapter 1 -- Glycoengineering of Vaccines That Harnessing the Natural Anti-Gal Antibody Increases Immune Protection in Viral Epidemics -- Abstract -- Introduction -- The Natural Anti-Gal Antibody Significance in Amplifying (-Gal Vaccine Immunogenicity -- The Natural Anti-Gal Antibody and the -Gal Epitope -- Evolutionary Causes for the Appearance of the Natural Anti-Gal Antibody -- Hypothesis on Anti-Gal Mediated Amplification of Viral Vaccine Immunogenicity -- Step 1 -- Step 2 -- Step 3 -- Synthesis of -Gal Epitopes on Viruses -- Experimental Animal Model for Production of Anti-Gal and Amplification of Viral Vaccine Immunogenicity by This Antibody -- Ova Containing (-Gal Liposomes as a Model for Viral (-Gal Vaccine -- Increased Efficacy of Influenza Virus -Gal Vaccine -- Increased Immunogenicity of HIV-gp120 Presenting -gal Epitopes as a Recombinant Glycoprotein Vaccine Model -- Synthesis of -Gal Epitopes on gp120 -- Amplification of Anti-HIV Immune Response Following Immunization with gp120 gal vs. gp120 Vaccines -- Targeting of Low Immunogenicity HIV Proteins to APC by Fusion with gp120 Gal -- Production and Immunogenicity of gp120 gal/p24 Vaccine -- Similarities between Mouse and Human Anti-Gal Antibodies -- Methods for Increasing Efficacy of Covid 19 Vaccines by Their Anti-Gal Mediated Targeting to APC -- Glycoengineering of -Gal Epitopes on Covid 19 Vaccines -- Potential Safety Issues with Future -Gal Vaccines in Humans -- Conclusion -- References -- Chapter 2 -- The Myopia Epidemic - A Worldwide Visual Concern -- Abstract -- Introduction -- Epidemiology -- Sequelae of Myopia -- Financial Burden of Myopia -- Pathogenesis -- Onset/Progression -- Environment -- Near Work -- Genetics -- Treatment -- Contact Lenses -- Orthokeratology -- MiSight -- Spectacles -- Atropine -- Pirenzepine -- Conclusion..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2021 ©2020 |
|---|---|
| Erschienen: |
New York: Nova Science Publishers, Incorporated ; 2021 ©2020 |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Paige, Edward [VerfasserIn] |
|---|
| Links: |
ebookcentral.proquest.com [lizenzpflichtig] |
|---|
| ISBN: |
|---|
| Themen: |
Communicable diseases |
|---|
| Anmerkungen: |
Description based on publisher supplied metadata and other sources |
|---|
| Umfang: |
1 online resource (152 pages) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1742638252 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1742638252 | ||
| 003 | DE-627 | ||
| 005 | 20240418083822.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201211s2021 xx |||||o 00| ||eng c | ||
| 020 | |a 9781536190250 |9 978-1-5361-9025-0 | ||
| 035 | |a (DE-627)1742638252 | ||
| 035 | |a (DE-599)KEP060605405 | ||
| 035 | |a (EBL)EBL6420551 | ||
| 035 | |a (EBC)EBC6420551 | ||
| 035 | |a (EBP)060605405 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | |a 614.4 |2 23 | |
| 100 | 1 | |a Paige, Edward |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epidemics |
| 264 | 1 | |a New York |b Nova Science Publishers, Incorporated |c 2021 | |
| 264 | 4 | |c ©2020 | |
| 300 | |a 1 online resource (152 pages) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Public Health in the 21st Century | |
| 490 | 0 | |a Public Health in the 21st Century Ser. | |
| 500 | |a Description based on publisher supplied metadata and other sources | ||
| 520 | |a Intro -- Contents -- Preface -- Chapter 1 -- Glycoengineering of Vaccines That Harnessing the Natural Anti-Gal Antibody Increases Immune Protection in Viral Epidemics -- Abstract -- Introduction -- The Natural Anti-Gal Antibody Significance in Amplifying (-Gal Vaccine Immunogenicity -- The Natural Anti-Gal Antibody and the -Gal Epitope -- Evolutionary Causes for the Appearance of the Natural Anti-Gal Antibody -- Hypothesis on Anti-Gal Mediated Amplification of Viral Vaccine Immunogenicity -- Step 1 -- Step 2 -- Step 3 -- Synthesis of -Gal Epitopes on Viruses -- Experimental Animal Model for Production of Anti-Gal and Amplification of Viral Vaccine Immunogenicity by This Antibody -- Ova Containing (-Gal Liposomes as a Model for Viral (-Gal Vaccine -- Increased Efficacy of Influenza Virus -Gal Vaccine -- Increased Immunogenicity of HIV-gp120 Presenting -gal Epitopes as a Recombinant Glycoprotein Vaccine Model -- Synthesis of -Gal Epitopes on gp120 -- Amplification of Anti-HIV Immune Response Following Immunization with gp120 gal vs. gp120 Vaccines -- Targeting of Low Immunogenicity HIV Proteins to APC by Fusion with gp120 Gal -- Production and Immunogenicity of gp120 gal/p24 Vaccine -- Similarities between Mouse and Human Anti-Gal Antibodies -- Methods for Increasing Efficacy of Covid 19 Vaccines by Their Anti-Gal Mediated Targeting to APC -- Glycoengineering of -Gal Epitopes on Covid 19 Vaccines -- Potential Safety Issues with Future -Gal Vaccines in Humans -- Conclusion -- References -- Chapter 2 -- The Myopia Epidemic - A Worldwide Visual Concern -- Abstract -- Introduction -- Epidemiology -- Sequelae of Myopia -- Financial Burden of Myopia -- Pathogenesis -- Onset/Progression -- Environment -- Near Work -- Genetics -- Treatment -- Contact Lenses -- Orthokeratology -- MiSight -- Spectacles -- Atropine -- Pirenzepine -- Conclusion. | ||
| 650 | 0 | |a Communicable diseases |x Prevention | |
| 650 | 0 | |a Epidemics | |
| 650 | 0 | |a Communicable diseases-Prevention | |
| 650 | 4 | |a Electronic books | |
| 776 | 1 | |z 9781536189766 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781536189766 |
| 856 | 4 | 0 | |u https://ebookcentral.proquest.com/lib/kxp/detail.action?docID=6420551 |m X:EBC |x Aggregator |z lizenzpflichtig |
| 912 | |a ZDB-30-PQE | ||
| 912 | |a BSZ-30-PQE-S2NUFH | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a ISIL_DE-Brg3 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_736 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a ISIL_DE-289 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a ISIL_DE-950 | ||
| 951 | |a BO | ||
| 953 | |2 045F |a 614.4 | ||
| 980 | |2 206 |1 01 |x 3350 |b 3827576733 |c 00 |f --%%-- |d Online-Ressource |e g |j --%%-- |h OLR-EBL |k If you are a ThHF affiliate and the E-Book is not fully accessible, please send us a purchase or short time loan request. All others: Inter-library loans and guest access on campus premises is not possible. |y zh |z 18-12-20 | ||
| 980 | |2 736 |1 01 |x 4736 |b 3823709771 |h EBC-Content |y zeg |z 11-12-20 | ||
| 980 | |2 2021 |1 01 |x DE-289 |b 3843984387 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |y l01 |z 28-01-21 | ||
| 980 | |2 2148 |1 01 |x DE-950 |b 4513356197 |c 00 |f --%%-- |d eBook ProQuest |e --%%-- |j n |k PDA-Angebot - nur für Hochschulangehörige der HfWU |y l01 |z 18-04-24 | ||
| 981 | |2 206 |1 01 |x 3350 |y Full Text only for ThHf affiliates |r https://thh-friedensau.idm.oclc.org/login?url=http://ebookcentral.proquest.com/lib/thhfriedensau/detail.action?docID=6420551 | ||
| 981 | |2 736 |1 01 |x 4736 |r https://ebookcentral.proquest.com/lib/staat/detail.action?docID=6420551 | ||
| 981 | |2 2021 |1 01 |x DE-289 |r https://ebookcentral.proquest.com/lib/kiz-uniulm/detail.action?docID=6420551 | ||
| 981 | |2 2148 |1 01 |x DE-950 |r https://ebookcentral.proquest.com/lib/hfwu/detail.action?docID=6420551 | ||
| 995 | |2 206 |1 01 |x 3350 |a OLR-EBL | ||
| 995 | |2 736 |1 01 |x 4736 |a EBC-Content | ||